Read more
Zusatztext 'Ansell's book dispels the current gloom of the pharma industry about its prospects. Not much conventional wisdom survives his lively and rigorous assessment of the opportunities open to the industry and for the more tuned in and strategically adaptive pharma companies to continue to execute successfully. An entertaining and well-argued case demonstrating why competence in new product development will continue to remain the value adding differentiator within the industry.' Fred Hassan! President! International Federation of Pharmaceutical Manufacturers Association (IFPMA) and Chairman! Bausch & Lomb 'This timely publication comes at a tipping point for Big Pharma faced with almost boundless opportunities from new medical sciences yet subject to intense pressure on market access and growth. It provides an in depth analysis of individual company performance; successes and failures and presents optimistic yet pragmatic suggestions to transform the current state of the pharmaceutical industry. Essential reading for professionals at all levels in the industry and for payers and patients! the book provides an incisive analysis of the drivers of change in healthcare provision; covers the complexity and dilemmas facing R&D and the challenges of market access and brand management and! in addition! is a valuable source book of data. It provides clarity as to how the pharmaceutical sector differs from other industries and why individual companies need to be clearly distinctive.' Prof Trevor M Jones CBE! former Director General ABPI 'It is refreshing to see the vital importance of new product development (and for business development executives the need for successful alliances) coming back into the spotlight after years of mega mergers and diversification that have failed to deliver transformative performance for Big Pharma companies. As such the book must be of interest to all Big Pharma companies as a sounding board for their strategic analysis and future direc Informationen zum Autor John Ansell has been an independent pharmaceutical industry consultant based in the UK since 1989. He is also a Senior Partner at the CRO TranScrip Partners. He has worked with pharmaceutical companies of all shapes and sizes! and with companies serving the industry - over 150 in all. Ansell concentrates on international projects with a commercial and strategic emphasis! reflecting his previous 20 years in the pharmaceutical industry in marketing and business development. A biochemistry graduate with a Master's degree in business studies! Ansell worked first in Holland for Organon and later there for Solvay! as well as in the UK for Schering AG! Fisons and Glaxo. Since 2007 he has been an Honorary Consultant to the University of Manchester School of Pharmacy and Pharmaceutical Sciences. Ansell is the author of 50 articles and reports on pharmaceutical issues and is a frequent speaker and chair at industry conferences (see www.johnansell.com). Klappentext Transforming Big Pharma addresses critically how strategy works in the pharmaceutical industry. John Ansell assesses the wide range of alternative strategies big pharma has been attempting in order to make up the shortfall in revenues stemming from the long-standing failure to develop sufficient new products. Zusammenfassung Transforming Big Pharma addresses critically how strategy works in the pharmaceutical industry. John Ansell assesses the wide range of alternative strategies big pharma has been attempting in order to make up the shortfall in revenues stemming from the long-standing failure to develop sufficient new products. Inhaltsverzeichnis Introduction; Part 1 How Pharma Differs and Why This Is Important; Chapter 1 How Pharma Differs; Chapter 2 The Consequences of Extended Timescales; Chapter 3 The Barriers to Getting In and Out of Pharmaceuticals; Part 2 Assessing Management Concepts for the Pharmaceutical I...
